what are the risks of glp-1 drugs Medications Infographic Part 2 of a 3-Part
Description
Yao ZG, Liu Y, Zhang L, et al
Special consideration is necessary when prescribing GLP-1 agonists in individuals with a history of eating disorders or other forms of psychiatric conditions, emphasizing pre-treatment screening akin to bariatric surgery protocols
Lastly, the overall statistical and clinical heterogenicity varied too widely to perform an adequate meta-analysis
Front Immunol (2020) 11:484
They can protect lean body mass and micronutrient status during weight loss (which is often rapid with GLP-1s)
Glucose-dependent insulin-releasing polypeptide (GIP) and GLP-1 are both secreted in response to food ingestion and potentiate the glucose-induced insulin response (figure 1)
